CAMBRIDGE, Mass., March 5, 2019 /PRNewswire/ -- BlueRock Therapeutics, LP, an engineered cell therapy company leveragingits novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock Therapeutics, will present at the Cowen and
About BlueRock Therapeutics BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock's Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock's cell differentiation technology recapitulates the cell's developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock's culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.
Investors:Candice Ellis, 978-879-7273Associate Director, Investor Relations and Corporate Communications firstname.lastname@example.org
Media Contacts: David Schull or Maggie Beller Russo Partners, LLC (646) 942-5631 Maggie.email@example.com
View original content:http://www.prnewswire.com/news-releases/bluerock-therapeutics-to-present-at-cowen-and-company-39th-annual-health-care-conference-300806258.html
SOURCE BlueRock Therapeutics
Subscribe to our Free Newsletters!